Article
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.
BioMed research international - 1 Jan 2016
Ruiz-Padilla A J, Gamez-Nava J I, Saldaña-Cruz A M, Murillo-Vazquez J D, Vazquez-Villegas M L, Zavaleta-Muñiz S A, Martín-Márquez B T, Ponce-Guarneros J M, Rodriguez Jimenez N A, Flores-Chavez A, Sandoval-Garcia F, Vasquez-Jimenez J C, Cardona-Muñoz E G, Totsuka-Sutto S E, Gonzalez-Lopez L
Abstract excerpt
Objective. To evaluate the association of -174G/C IL-6 polymorphism with failure in therapeutic response to methotrexate (MTX) or leflunomide (LEF). This prospective, observational cohort included 96 Mexican-Mestizo patients with moderate or severe rheumatoid arthritis (RA), initiating MTX or LEF, genotyped for IL-6 -174G/C polymorphism by PCR-RFLP. Therapeutic response was strictly defined: only if patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.